News | March 10, 2008

Bayer HealthCare Opens New Door to Tracking Contrast Media

March 11, 2008 – Bayer HealthCare Pharmaceuticals Inc. unveiled plans to launch VistaTrak, a contrast media management system that provides a new management tool designed to help enhance patient care and safety, optimize inventory management and improve billing accuracy.

VistaTrak is a collaboration between Bayer HealthCare Pharmaceuticals and Mobile Aspects, a provider of Radio Frequency Identification (RFID)-enabled solutions for healthcare and hospital environments. The companies worked together to optimize Mobile Aspects’ proprietary iRIS platform for clinical environments that use contrast media. Bayer is the first company to offer a contrast media management system based on an RFID platform to automate manual processes and capture valuable operational data that currently cannot be found in any one system.

The system combines RFID technology of “tagged” bottles of contrast agent with a “smart” cabinet and a specially designed interface to capture, store and manage product utilization data easily and reliably while helping to reduce the risk of human error. It provides solutions for the use of contrast media, such as:
• Facilitating patient safety by automatically screening data from a patient’s electronic medical record (EMR) for, among other things, contraindications and prior adverse events
• Capturing information stored on the tag, such as NDC number, expiration date and lot number, automatically and in an efficient manner that supports compliance with accrediting organization requirements
• Providing contrast dosing information to improve billing accuracy and help address any existing issues with reimbursement or audits
• Tracking inventory to enable departments to order and manage inventory more efficiently and reduce waste

VistaTrak features a touch-screen interface and is available in two different sizes to address varying usage needs.

For more information: www.pharma.bayer.com

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init